leadf
logo-loader
viewAerie Pharmaceuticals

Aerie Pharmaceuticals in spotlight as FDA judges Rhopressa eye drop

The FDA will decide on Aerie’s Rhopressa eye drop this morning

eye
The stock's trading was halted

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.

Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.

Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.

Quick facts: Aerie Pharmaceuticals

Price: 11.21 USD

NASDAQ:AERI
Market: NASDAQ
Market Cap: $521.43 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

GinsGlobal Managing Director sees Healthcare and Healthcare innovation as...

HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...

1 day, 22 hours ago

2 min read